NZ612796A - A ca6 antigen-specific cytotoxic conjugate and methods of using the same - Google Patents

A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Info

Publication number
NZ612796A
NZ612796A NZ612796A NZ61279604A NZ612796A NZ 612796 A NZ612796 A NZ 612796A NZ 612796 A NZ612796 A NZ 612796A NZ 61279604 A NZ61279604 A NZ 61279604A NZ 612796 A NZ612796 A NZ 612796A
Authority
NZ
New Zealand
Prior art keywords
fragment
chain variable
variable region
antigen
methods
Prior art date
Application number
NZ612796A
Other languages
English (en)
Inventor
Gillian Payne
Philip Chun
Daniel J Tavares
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34102763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ612796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NZ612796A publication Critical patent/NZ612796A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
NZ612796A 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same NZ612796A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48844703P 2003-07-21 2003-07-21
NZ598504A NZ598504A (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (1)

Publication Number Publication Date
NZ612796A true NZ612796A (en) 2015-02-27

Family

ID=34102763

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ612796A NZ612796A (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same
NZ598504A NZ598504A (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same
NZ580855A NZ580855A (en) 2003-07-21 2004-07-21 A CA6 antigen-specific cytotoxic conjugate and methods of using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ598504A NZ598504A (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same
NZ580855A NZ580855A (en) 2003-07-21 2004-07-21 A CA6 antigen-specific cytotoxic conjugate and methods of using the same

Country Status (26)

Country Link
US (1) US20050123549A1 (enExample)
EP (1) EP1660513B9 (enExample)
JP (5) JP2007503202A (enExample)
KR (5) KR101263950B1 (enExample)
CN (3) CN103554261B (enExample)
AT (1) ATE496944T1 (enExample)
AU (1) AU2004258955C1 (enExample)
BR (1) BRPI0412879A8 (enExample)
CA (1) CA2532430C (enExample)
CR (1) CR8207A (enExample)
CY (1) CY1111938T1 (enExample)
DE (1) DE602004031239D1 (enExample)
DK (1) DK1660513T5 (enExample)
EA (1) EA014640B1 (enExample)
EC (1) ECSP066294A (enExample)
ES (1) ES2360403T3 (enExample)
HR (1) HRP20110302T1 (enExample)
IL (2) IL172982A (enExample)
MX (2) MXPA06000830A (enExample)
NO (1) NO339324B1 (enExample)
NZ (3) NZ612796A (enExample)
PL (1) PL1660513T3 (enExample)
PT (1) PT1660513E (enExample)
SI (1) SI1660513T1 (enExample)
WO (1) WO2005009369A2 (enExample)
ZA (1) ZA200600375B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US9539348B2 (en) 2000-08-18 2017-01-10 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PT1651162E (pt) * 2003-05-20 2016-02-22 Immunogen Inc Agentes citotóxicos melhorados compreendendo novos maitansinóides
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EA020130B9 (ru) * 2005-08-22 2014-10-30 Иммьюноджен, Инк. Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
EP2019104B1 (en) 2007-07-19 2013-09-04 Sanofi Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX341344B (es) * 2007-12-26 2016-08-16 Biotest Ag Agentes dirigidos a cd138 y sus usos.
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
KR20100097753A (ko) * 2007-12-26 2010-09-03 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
RU2015128833A (ru) * 2009-05-06 2015-11-10 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
CA2824143C (en) * 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
CA2843771A1 (en) * 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
KR20140100571A (ko) 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
WO2014122529A1 (en) 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
CN105051521B (zh) 2013-03-15 2020-03-24 贝克曼考尔特公司 用于设计流式细胞术中的面板的系统和方法
CN105592861A (zh) * 2013-08-02 2016-05-18 赛诺菲 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
KR20160125515A (ko) * 2014-03-12 2016-10-31 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
EP3188761A4 (en) 2014-09-02 2018-04-18 ImmunoGen, Inc. Methods for formulating antibody drug conjugate compositions
DK3189056T3 (da) 2014-09-03 2020-09-14 Immunogen Inc Cytotoksiske benzodiazepinderivater
JP2017527562A (ja) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド 細胞毒性ベンゾジアゼピン誘導体
CN108025084B (zh) 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
CA3018630A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP7174704B2 (ja) 2016-12-21 2022-11-17 バイエル・アクチエンゲゼルシヤフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
RU2761390C2 (ru) 2016-12-21 2021-12-07 Байер Фарма Акциенгезельшафт Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
EP3589328A1 (en) 2017-02-28 2020-01-08 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
JP7684947B2 (ja) 2019-03-19 2025-05-28 フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン 癌の治療のための併用療法
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CA3240270A1 (en) * 2022-02-03 2023-08-10 Keyu LI Anti-cd38 binding molecules and uses thereof
CN120166937A (zh) 2022-10-25 2025-06-17 佩普托米克公司 用于治疗癌症的联合疗法
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
CN121335714A (zh) 2023-06-07 2026-01-13 瓦尔希伯伦私人肿瘤研究基金会 用于治疗癌症的与mek抑制剂的组合疗法
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0605522B1 (en) * 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994011026A2 (en) * 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
DK1242401T3 (da) * 1999-11-24 2007-05-07 Immunogen Inc Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2005523681A (ja) * 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
WO2003043583A2 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20030228305A1 (en) * 2002-01-02 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EA009285B1 (ru) * 2003-05-14 2007-12-28 Иммуноджен, Инк. Композиция конъюгированного лекарственного средства

Also Published As

Publication number Publication date
AU2004258955C1 (en) 2012-07-26
JP2016128405A (ja) 2016-07-14
PL1660513T3 (pl) 2011-08-31
NO20060812L (no) 2006-04-20
EP1660513A4 (en) 2007-07-04
DK1660513T5 (da) 2011-07-18
JP5643619B2 (ja) 2014-12-17
CN103554261B (zh) 2017-03-01
MX336469B (es) 2016-01-18
AU2004258955B2 (en) 2011-12-01
CR8207A (es) 2008-11-12
ZA200600375B (en) 2006-12-27
EA014640B1 (ru) 2010-12-30
JP5997727B2 (ja) 2016-09-28
KR20140047739A (ko) 2014-04-22
CN103145844A (zh) 2013-06-12
MXPA06000830A (es) 2006-04-18
DE602004031239D1 (de) 2011-03-10
DK1660513T3 (da) 2011-05-16
IL242336A (en) 2017-08-31
JP6144749B2 (ja) 2017-06-07
CA2532430A1 (en) 2005-02-03
ATE496944T1 (de) 2011-02-15
KR20150126732A (ko) 2015-11-12
KR20120059657A (ko) 2012-06-08
KR20120113811A (ko) 2012-10-15
IL172982A (en) 2015-11-30
BRPI0412879A (pt) 2006-10-03
JP2011092194A (ja) 2011-05-12
CN103145844B (zh) 2016-08-03
HK1185891A1 (zh) 2014-02-28
CN103554261A (zh) 2014-02-05
WO2005009369A2 (en) 2005-02-03
EP1660513A2 (en) 2006-05-31
JP2007503202A (ja) 2007-02-22
NZ580855A (en) 2012-03-30
PT1660513E (pt) 2011-05-03
EP1660513B9 (en) 2012-04-04
CA2532430C (en) 2016-12-13
CY1111938T1 (el) 2015-11-04
EP1660513B1 (en) 2011-01-26
KR101565721B1 (ko) 2015-11-03
ES2360403T3 (es) 2011-06-03
NZ598504A (en) 2013-08-30
JP2015012861A (ja) 2015-01-22
KR101672664B1 (ko) 2016-11-04
ECSP066294A (es) 2006-07-28
JP2017123857A (ja) 2017-07-20
HRP20110302T1 (hr) 2011-06-30
CN1922199A (zh) 2007-02-28
WO2005009369A3 (en) 2005-06-30
SI1660513T1 (sl) 2011-06-30
HK1098160A1 (en) 2007-07-13
KR20060054331A (ko) 2006-05-22
CN1922199B (zh) 2013-10-30
BRPI0412879A8 (pt) 2015-12-15
AU2004258955A1 (en) 2005-02-03
KR101263950B1 (ko) 2013-05-31
US20050123549A1 (en) 2005-06-09
IL172982A0 (en) 2006-06-11
EA200600275A1 (ru) 2006-08-25
NO339324B1 (no) 2016-11-28

Similar Documents

Publication Publication Date Title
NZ612796A (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
NZ596295A (en) Anti-5T4 antibodies and uses thereof
SG156547A1 (en) Human monoclonal antibodies to ctla-4
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
NZ593068A (en) IL-18 antibody
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ547157A (en) Interferon Alpha Antibodies and their uses
NZ599683A (en) Anti-ilt7 antibody
SG151284A1 (en) Antibodies against ccr5 and uses thereof
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2008017828A3 (en) Antibodies specific for human cd98 heavy antigen
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
WO2006087637A3 (en) Anti her2/neu antibody
MX2025004739A (es) Anticuerpo anti-cd16a y aplicacion del mismo
EP2261253A3 (en) Antibodies directed to Clostridium difficile
WO2003016501A3 (en) Recombinant antibodies, and compositions and methods for making and using the same

Legal Events

Date Code Title Description
PSEA Patent sealed
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: PATENT SPECIFICATION; FILING DATE: 05 JUL 2013; STATUS: REJECTED; TITLE: PATENT SPECIFICATION; FILING DATE: 02 OCT 2014; STATUS: REJECTED; TITLE: A CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF USING THE SAME; FILING DATE: 28 JAN 2015; STATUS: OVERWRITTEN; PUBLICATION DATE: 27 FEB 2015; TITLE: A CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF USING THE SAME ; FILING DATE: 20 MAY 2015; STATUS: GRANTED; TITLE: A CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF USING THE SAME; FILING DATE: 28 JAN 2015; STATUS: SUPERSEDED; PUBLICATION DATE: 27 FEB 2015;

Effective date: 20150831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 21 JUL 2017 BY AJ PARK

Effective date: 20150922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2018 BY CPA GLOBAL

Effective date: 20170629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUL 2019 BY CPA GLOBAL

Effective date: 20180607

LAPS Patent lapsed